Trial Profile
AGN-229666 for the Treatment of Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2014
Price :
$35
*
At a glance
- Drugs Alcaftadine (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Allergan
- 17 Feb 2014 New trial record